Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9174252 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL11338420 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL8750284 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL15993932 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL11336824 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL4251988 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL25341537 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL516346 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL8957984 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL10683264 | 1.00 | KCNH2 (0.57) | KCNH2DNM1PLA2G1BPLA2G2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| WO-2023193892-A1 | NUCLEIC ACID COMPOSITIONS COMPRISING AN INORGANIC POLYPHOSPHATE AND METHODS FOR PREPARING, STORING AND USING THE SAME | BioNTech SE (DE) | 2023-10-12 | — | — | WO | disclosed |
| EP-0421327-A1 | Heavy duty laundry detergent | ALBEMARLE CORPORATION (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | KCNH2 3603/4885DNM1 307/4885PLA2G1B 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.